✦ LIBER ✦

The impact of race and ethnicity on transference and countertransference in combined individual/group therapy

✍ Scribed by Judith C. White

Publisher: Springer
Year: 1994
Tongue: English
Weight: 820 KB
Volume: 18
Category: Article
ISSN: 0362-4021
DOI: 10.1007/bf01457420

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of initial quality control review

Impact of initial quality control review on study outcome in lung and head/neck cancer studies—review of the radiation therapy oncology group experience

✍ Paul E. Wallner; Robert A. Lustig; Thomas F. Pajak; Gregg Robinson; Lawrence W. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 760 KB

Impact of the timing of triple intrathec

Impact of the timing of triple intrathecal therapy on remission induction in childhood acute lymphoblastic leukemia: A pediatric oncology group study

✍ Hvizdala, Eva ;Berry, D. H. ;Chen, Timothy ;Dyment, Paul G. ;Kim, Tae H. ;Steube 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB

Five weekly doses of triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment were added to systemic induction therapy in a regimen (Arm 3) that was compared to three other regimens (Arms 1, 2, and 4) in which central nervous system (CN

French gene therapy group reports on the

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position statement from the European Society of Gene Therapy (ESGT)

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

## Position statement from the European Society of Gene Therapy (ESGT) Background News of a serious adverse event in a clinical trial of gene therapy for inherited, X chromosome-linked Severe Combined Immunodeficiency (X-SCID) was made public on October 2, 2002, by the group of French scientists p

Impact of chemotherapy regimens prior to

Impact of chemotherapy regimens prior to endocrine therapy : Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial

✍ Aman U. Buzdar; Jean-Paul Guastalla; Jean-Marc Nabholtz; Jack Cuzick; on behalf 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

The clinical impact and molecular biolog

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

✍ Kevin D. Boyd; Fiona M. Ross; William J. Tapper; Laura Chiecchio; GianPaolo Dagr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 1 views

## Abstract Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of thalidomide therapy is not well described. The clinical outcome of 85 myeloma patients with del(17p) treated in a clinical trial incor

Clinical update: Impact of Adjuvant Ther

Clinical update: Impact of Adjuvant Therapy on Quality of Life in Women with Node Positive Operable Breast Cancer. Hurny, C., Bernhard, J., Coates, A.S., Castiglione-Gertsch, M., Peterson, H.F. et al. for the International Breast Cancer Study Group (1996) 347, No. 9011, 1279–1284.

✍ William Breitbart; Ann Cull; Donna Greenberg 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views